<html><head></head><body><h1>Fluorouracil (Systemic)</h1><p class="drug-subtitle"><b>Class:</b> Antineoplastic Agents<br/>
<b>VA Class:</b> AN300<br/>
<b>Chemical Name:</b> 5-fluoro-2,4(1H,3H)-Pyrimidinedione<br/>
<b>Molecular Formula:</b> C<sub>4</sub>H<sub>3</sub>FN<sub>2</sub>O<sub>2</sub><br/>
<b>CAS Number:</b> 51-21-8<br/>
<b>Brands:</b> Adrucil</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h3>Warning</h3><ul>
<li>
<p>Only for administration by, or under the supervision of, a clinician experienced in cancer chemotherapy and the use of antimetabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Severe toxic reactions are possible; hospitalize patients, at least during initial course of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Only for administration by, or under the supervision of, a clinician experienced in cancer chemotherapy and the use of antimetabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe toxic reactions are possible; hospitalize patients, at least during initial course of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Introduction</h2><p>Pyrimidine antagonist; antimetabolite; antineoplastic agent.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Fluorouracil (Systemic)</h2><h3>Cancers</h3><p>Principally for GI, breast, and head and neck cancers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Palliative treatment of carcinoma of the colon, rectum, anus, stomach, biliary tract, esophagus, and pancreas that is not amenable to surgery or irradiation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjunct to surgery for the treatment of various solid tumors (e.g., adenocarcinoma of the colon,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;226&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;232&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;233&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;252&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;253&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; rectal carcinoma).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;234&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;235&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;236&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;237&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;239&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;240&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;243&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Colorectal Cancer</h3><p>Drug of choice (combined with leucovorin) as an adjunct to surgery for colorectal cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Drug of choice (combined with leucovorin and other drugs [e.g., irinotecan, oxaliplatin]) for metastatic colorectal cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Combination fluorouracil/leucovorin regimens have replaced fluorouracil monotherapy regimens&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;294&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;295&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;296&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;300&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;305&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; as adjuvant therapy for stage III disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Weekly schedule of fluorouracil/leucovorin (high-dose leucovorin or Roswell Park regimen) has equal efficacy as monthly schedule (low-dose or Mayo Clinic schedule), but the weekly schedule is a preferred regimen for adjuvant therapy because of ease of use and less toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;386&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Colorectal Cancer under Dosage and Administration.)</p><p>Bimonthly, continuous IV infusion schedule of fluorouracil/leucovorin (LV5FU2 or deGramont regimen)† also evaluated as adjuvant therapy&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;390&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and shown to be safer than direct IV injection regimen of these drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;390&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Simplified version of this regimen also evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;391&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Colorectal Cancer under Dosage and Administration.)</p><p>Role of regional adjuvant therapy (e.g., portal vein or hepatic artery infusion†) for liver metastases requires further elucidation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;253&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;258&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;264&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;275&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Leucovorin and levoleucovorin enhance cytotoxicity,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;291&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;305&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;307&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;308&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;309&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;310&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;397&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; potentiate fluorouracil antineoplastic activity, and improve response for palliative advanced colorectal carcinoma treatment;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;287&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;288&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;290&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;291&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;293&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;294&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;295&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;296&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;297&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;298&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;299&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;300&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;301&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;305&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;311&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;313&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;314&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;315&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;317&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; designated an orphan drug by FDA for use with leucovorin for metastatic colorectal adenocarcinoma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;335&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Leucovorin and levoleucovorin may potentiate risk of fluorouracil GI toxicity (e.g., diarrhea, nausea, stomatitis, vomiting) and myelosuppression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;217&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;293&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;294&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;295&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;296&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;311&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Esophageal Cancer</h3><p>Drug of choice for treatment of esophageal cancer†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been used alone&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;330&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;334&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;336&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and in combination therapy (e.g., with cisplatin)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;330&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;331&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;334&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;336&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; for the treatment of localized or advanced esophageal cancer†.</p><h3>Gastric Cancer</h3><p>Drug of choice (with or without leucovorin and/or other drugs [e.g., cisplatin, epirubicin]) for treatment of gastric cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Anal Cancer</h3><p>Drug of choice (e.g., combined with mitomycin or cisplatin) for treatment of anal cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Pancreatic Cancer</h3><p>Drug of choice as adjunct to surgery and for localized unresectable pancreatic cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Biliary Tract Cancer</h3><p>Drug of choice (with or without leucovorin) for treatment of biliary tract cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Breast Cancer</h3><p>Drug of choice combined with other drugs (e.g., cyclophosphamide and doxorubicin or methotrexate) as an adjunct to surgery and for metastatic breast cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;244&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;251&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;279&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;319&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;322&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;324&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;325&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;326&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Palliative treatment of carcinoma of the breast not amenable to surgery or irradiation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjunct to surgery, may improve outcome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;244&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;245&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;246&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;247&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;248&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;250&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;251&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;254&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;270&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;271&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;272&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been used most extensively with cyclophosphamide and methotrexate, and is considered a regimen of choice.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;244&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;251&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;279&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;319&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;322&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;324&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;325&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;326&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Head and Neck Cancer</h3><p>Drug of choice combined with cisplatin for head and neck cancer†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In combination chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been used in combination chemotherapy with radiation therapy for palliative treatment of unresectable locally advanced head and neck cancer,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;337&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and for larynx preservation in locally advanced laryngeal or hypopharyngeal cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;354&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;355&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;356&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;357&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used in combination with docetaxel and cisplatin as induction therapy prior to radiotherapy or chemoradiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;393&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;394&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Cervical Cancer</h3><p>Drug of choice combined with other drugs (e.g., cisplatin) for treatment of locally advanced cervical cancer†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In combination with cisplatin concurrently with radiation therapy for invasive cervical cancer†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;359&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;360&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;361&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;362&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;364&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Metastatic or recurrent cervical cancer†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;365&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;366&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;367&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;369&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;370&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;371&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Renal Cell Carcinoma</h3><p>Has been used alone&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;374&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or in combination regimens&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;375&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;376&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;377&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;378&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;379&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;380&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;381&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;382&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;383&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;384&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; for the treatment of metastatic renal cell carcinoma†.</p><h3>Carcinoid Tumors</h3><p>Drug of choice for treatment of carcinoid tumors†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Other Uses</h3><p>Second-line therapy in the treatment of ovarian epithelial cancer†, including platinum-refractory disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also, cancers of the liver† (e.g., hepatoblastoma†).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;249&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Fluorouracil (Systemic) Dosage and Administration</h2><h3>Administration</h3><p>Administer IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been administered by regional infusion into the venous or arterial blood supply of a tumor† (e.g., portal vein or hepatic artery infusions for liver metastases).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;253&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;258&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;264&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;275&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>2.5- or 5-g pharmacy bulk package is intended for individual dose preparation, <i>not</i> for direct IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid extravasation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No dilution necessary for usual injection formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer through a 25-gauge needle at any convenient rate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Base dosage on actual weight.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Base dosage on estimated lean body mass if patient is obese or has fluid retention.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May calculate dosage based on body surface area.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;275&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;293&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;294&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;295&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;296&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;298&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;300&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;305&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;317&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;322&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Base dosage on clinical and hematologic response and patient tolerance to obtain optimum results with minimum adverse effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult published protocols for the dosage and method and sequence of administration of fluorouracil with other chemotherapeutic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, manufacturers recommend a course of 12 mg/kg once daily for 4 consecutive days, up to 800 mg daily; then (if toxicity does not preclude) administer 6 mg/kg on the 6th, 8th, 10th and 12th days (unless toxicity occurs before then).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Poor risk and inadequate nutrition: initially, manufacturers suggest a course of 6 mg/kg daily for 3 days, up to 400 mg daily; then (if toxicity does not preclude) may administer 3 mg/kg on the 5th, 7th, and 9th days (unless toxicity occurs before then).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Repeat courses: adjust schedule according to reaction to the previous course.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Repeat course at 30-day intervals if toxicity has not been a problem.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternatively, when toxicity of initial course has subsided, may administer 10–15 mg/kg (up to 1 g) once weekly for maintenance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Various fluorouracil/leucovorin combination dosage regimens have been used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;296&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;298&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;305&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;317&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Leucovorin 20 mg/m<sup>2</sup> IV <i>or</i> levoleucovorin 10 mg/m<sup>2</sup> IV followed by fluorouracil 425 mg/m<sup>2</sup> IV; administer fluorouracil and either leucovorin or levoleucovorin daily for 5 consecutive days and repeat regimen at 4-week intervals for 2 additional courses; thereafter, may repeat the regimen at intervals of 4–5 weeks provided toxicity from the previous course has resolved completely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;386&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Frequently administered for a total of 6 cycles in the adjuvant setting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;386&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternatively, leucovorin 200 mg/m<sup>2</sup> IV <i>or</i> levoleucovorin 100 mg/m<sup>2</sup> IV over ≥3 minutes followed by fluorouracil 370 mg/m<sup>2</sup> IV; administer fluorouracil and either leucovorin or levoleucovorin daily for 5 consecutive days and repeat regimen at 4-week intervals for 2 additional courses; thereafter, may repeat the regimen at intervals of 4–5 weeks provided toxicity from the previous course has resolved completely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;397&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjust fluorouracil dosage in subsequent courses according to tolerance;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; reduce daily fluorouracil dosage by 20% for moderate hematologic or GI toxicity in prior course and by 30% for severe toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (leucovorin or levoleucovorin dosage is not adjusted&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ).</p><p>May increase fluorouracil dosage by 10% if no toxicity occurred in the prior course.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Leucovorin 500 mg/m<sup>2</sup> as a 2-hour IV infusion followed by fluorouracil 500 mg/m<sup>2</sup> as a slow IV injection administered 1 hour after the start of the leucovorin infusion†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;386&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Administer both drugs weekly for 6 consecutive weeks followed by a 2-week rest; repeat cycles every 8 weeks for a total of 4 courses in the adjuvant setting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;386&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;388&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjust fluorouracil dosage in subsequent courses according to tolerance;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; reduce daily fluorouracil dosage by 20% for moderate hematologic or GI toxicity in prior course and by 30% for severe toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (leucovorin dosage is not adjusted&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ).</p><p>May increase fluorouracil dosage by 10% if no toxicity occurred in the prior course.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Leucovorin 400 mg/m<sup>2</sup> as a 2-hour IV infusion on day 1 followed by fluorouracil 400 mg/m<sup>2</sup> as an IV injection on day 1; then fluorouracil 1500 mg/m<sup>2</sup> as a continuous IV infusion over 23 hours on days 1 and 2 (i.e., total 3000 mg/m<sup>2</sup> by continuous IV infusion over 46 hours);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;391&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; repeat cycles every 2 weeks.</p><p>Various combination regimens have been used; consult published protocols for dosages and method and sequence of administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;246&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;269&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;271&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;272&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;322&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;324&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;325&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;326&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid <i>arbitrary</i> dose reductions of adjuvant combination chemotherapy; dose intensity appears to be an important factor influencing clinical outcome in early node-positive breast cancer (increasing response with increasing intensity).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;244&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;322&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Regimen containing IV fluorouracil in combination with oral cyclophosphamide and IV methotrexate is described in the table.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Drug</p><p>Dose</p><p>Administration Days per Cycle</p><p>Fluorouracil</p><p>600 mg/m<sup>2</sup> IV (≤60 yrs of age)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Days 1 and 8&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cyclophosphamide</p><p>100 mg/m<sup>2</sup> orally&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Days 1 through 14 &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Methotrexate</p><p>40 mg/m<sup>2</sup> IV (≤60 yrs of age)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Days 1 and 8 &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Repeat monthly (i.e., allow a 2-week rest period between cycles).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Total of 6–12 cycles (i.e., 6–12 months of therapy); clinical superiority between 6- versus 12-month regimens not demonstrated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;244&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;319&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initial fluorouracil and methotrexate dosages have been reduced in patients &gt;60 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Geriatric Patients under Special Populations.)</p><p>Also, dosage was reduced if myelosuppression developed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In early breast cancer and &gt;3 positive axillary lymph nodes, doxorubicin addition may improve outcome, and sequential regimens (i.e., several courses of doxorubicin first) may be more effective than alternating regimens; no additional benefit when fewer positive nodes are present.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;326&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, doxorubicin hydrochloride 75 mg/m<sup>2</sup> IV at 3-week intervals for 4 doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Subsequently, fluorouracil 600 mg/m<sup>2</sup> IV, methotrexate 40 mg/m<sup>2</sup> IV, and cyclophosphamide 600 mg/m<sup>2</sup> IV at 3-week intervals for 8 cycles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Total of about 9 months of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Generally, myelosuppression has delayed cycle rather than reducing dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Initially (first 4 days), manufacturers recommend maximum of 800 mg daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Poor risk and inadequate nutrition: manufacturers recommend initially (first 3 days) maximum of 400 mg daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternative dosage for maintenance once toxicity of initial course has subsided: manufacturers recommend maximum of 1 g once weekly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>In patients &gt;60 years of age receiving oral cyclophosphamide, IV methotrexate, and IV fluorouracil combination therapy, reduce initial methotrexate dosage to 30 mg/m<sup>2</sup> and fluorouracil dosage to 400 mg/m<sup>2</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Fluorouracil (Systemic)</h2><h3>Contraindications</h3><ul>
<li>
<p>Poor nutritional state.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Depressed bone marrow function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Potentially serious infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Known hypersensitivity to fluorouracil.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Poor nutritional state.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Depressed bone marrow function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potentially serious infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Known hypersensitivity to fluorouracil.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Do not exceed 800 mg daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use extreme caution in patients with history of high-dose pelvic irradiation, previous use of alkylating agents, widespread bone marrow metastases, impaired hepatic or renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Deficiency of dipyrimidine dehydrogenase activity may cause prolonged fluorouracil clearance and toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe, unexpected toxic reactions (including stomatitis, diarrhea, neutropenia, and neurotoxicity) have been reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Rechallenge with fluorouracil (at a reduced dosage) has caused recurrent, progressive toxicity and increased morbidity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise women to avoid becoming pregnant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform women who become pregnant while taking fluorouracil that there is a potential hazard to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use during pregnancy only if the potential benefit justifies the risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Any therapy that adds stress, interferes with nutrition, or depresses bone marrow function will increase fluorouracil toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Extreme caution when combined with leucovorin or levoleucovorin in geriatric or debilitated patients, since they are more likely to develop serious fluorouracil toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Interactions and also see GI Toxicity under Cautions.)</p><p>Palmar-plantar erythrodysesthesia (hand-foot syndrome); in some cases, with prolonged infusions of high dosages.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;206&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Erythematous, desquamative rash that involves the hands and feet,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;206&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; may be accompanied by tingling or painful hands and feet, swollen palms and soles, and phalangeal tenderness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Effects may gradually disappear over 5–7 days after fluorouracil discontinuance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May be treated with oral pyridoxine therapy, but safety and efficacy of pyridoxine for this condition have not been fully established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Highly toxic, very low therapeutic index; therapeutic response is unlikely without some evidence of toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Boxed Warning.)</p><p>May produce severe hematologic toxicity, GI hemorrhage, and even death.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe toxicity most likely in poor risk patients, but fatality may occur even in those in relatively good condition.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue promptly at first visible sign of stomatitis or esophagopharyngitis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue promptly for intractable vomiting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue promptly for diarrhea, frequent bowel movements, watery stools.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Potential for diarrhea to result in rapid clinical deterioration and death in patients receiving reduced folates (leucovorin, levoleucovorin) concomitantly; close monitoring is required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;315&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue promptly for GI ulceration and bleeding.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue promptly for leukopenia (WBC &lt; 3500/mm<sup>3</sup>) or rapidly falling WBC;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; place in protective isolation and take appropriate measures for prevention of infection if the leukocyte count drops to &lt; 2000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue promptly for thrombocytopenia (platelets &lt; 100,000/mm<sup>3</sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue promptly for hemorrhage from any site.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category D.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Fetal/Neonatal Morbidity and Mortality under Cautions.)</p><p>Not known whether fluorouracil is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue nursing while receiving the drug; fluorouracil inhibits DNA, RNA, and protein synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy in children not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Stomatitis, esophagopharyngitis, anorexia, nausea, vomiting, diarrhea, leukopenia (principally granulocytopenia), thrombocytopenia, anemia, alopecia, dermatitis (principally pruritic maculopapular rash).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Fluorouracil (Systemic)</h2><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Leucovorin</p><p>Leucovorin potentiates cytotoxicity of fluorouracil in certain GI cancers&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;221&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;223&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;224&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;253&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;263&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;267&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Leucovorin enhances fluorouracil toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used to therapeutic advantage in GI cancers&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;201&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;202&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;203&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;204&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;212&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;215&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;219&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;253&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use concomitantly with extreme caution in geriatric or debilitated patients; more likely to develop serious toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Levoleucovorin</p><p>Levoleucovorin enhances therapeutic effects of fluorouracil in colorectal cancer&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Levoleucovorin enhances fluorouracil toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used to therapeutic advantage in colorectal cancer&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;397&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use concomitantly with extreme caution in geriatric or debilitated patients; more likely to develop serious toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;214&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;315&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;395&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Fluorouracil (Systemic) Pharmacokinetics</h2><h3>Distribution</h3><p>Distributed into tumors, intestinal mucosa, bone marrow, liver, and other tissues.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Readily crosses the blood-brain barrier (despite limited lipid solubility), and distributes into CSF and brain tissue.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usually higher concentration of fluorouracil or metabolites in tumor than in surrounding tissue or in corresponding normal tissue, and persists longer in some tumors than in the normal host tissues, perhaps due to impaired uracil catabolism; suggests some tumor specificity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Crosses the placenta in rats.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Not known whether fluorouracil is distributed into human milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>A small portion is anabolized in tissues to 5-fluoro-2′-deoxyuridine, then to active metabolite (5-fluoro-2′-deoxyuridine-5′-monophosphate).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The major portion is degraded in the liver, to inactive metabolites (e.g., CO<sub>2</sub>, urea, α-fluoro-β-alanine, α-fluoro-β-guanidopropionic acid, and α-fluoro-β-ureidopropionic acid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>7–20% is excreted unchanged in urine within 6 hours; &gt;90% of this in the 1st hour.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inactive metabolites are excreted as respiratory CO<sub>2</sub> and (in urine) as urea, α-fluoro-β-alanine, α-fluoro-β-guanidopropionic acid, and α-fluoro-β-ureidopropionic acid.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>About 16 minutes (range: 8–20 minutes) and is dose dependent; no intact drug is detected in plasma after 3 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>Discard unused portion of 2.5 or 5 g pharmacy bulk package 1 hour after the vial has been entered.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–30°C;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; do not freeze, protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Slight discoloration during storage does not adversely affect potency or safety.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Fluorouracil precipitation occurs commonly, particularly following exposure to low temperatures.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;274&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Dissolve precipitate by heating to 60°C and shaking vigorously; cool to body temperature before using.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ease of dissolution may depend on the crystal size and location (e.g., those lodged between the stopper and glass container).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;274&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Attempts to dissolve precipitate with heat and agitation may be unsuccessful.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;274&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Store in adequately heated areas during cold weather to minimize frequency of precipitation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;274&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Amino acids 4.25%, dextrose 25%</p><p>Dextrose 5% in Ringer’s injection, lactated</p><p>Dextrose 5% in water</p><p>Sodium chloride 0.9%</p><p>Compatible</p><p>Bleomycin sulfate</p><p>Cyclophosphamide</p><p>Cyclophosphamide with methotrexate sodium</p><p>Etoposide</p><p>Floxuridine</p><p>Hydromorphone HCl</p><p>Ifosfamide</p><p>Methotrexate sodium</p><p>Mitoxantrone HCl</p><p>Vincristine sulfate</p><p>Incompatible</p><p>Carboplatin</p><p>Ciprofloxacin</p><p>Cisplatin</p><p>Cytarabine</p><p>Diazepam</p><p>Doxorubicin HCl</p><p>Epirubicin HCl</p><p>Fentanyl citrate</p><p>Leucovorin calcium</p><p>Metoclopramide HCl</p><p>Morphine sulfate</p><p>Compatible</p><p>Allopurinol sodium</p><p>Amifostine</p><p>Anidulafungin</p><p>Aztreonam</p><p>Bleomycin sulfate</p><p>Cisplatin</p><p>Cyclophosphamide</p><p>Doripenem</p><p>Doxorubicin HCl</p><p>Doxorubicin HCl liposome injection</p><p>Etoposide phosphate</p><p>Fludarabine phosphate</p><p>Furosemide</p><p>Gemcitabine HCl</p><p>Granisetron HCl</p><p>Heparin sodium</p><p>Hydrocortisone sodium succinate</p><p>Leucovorin calcium</p><p>Linezolid</p><p>Mannitol</p><p>Melphalan HCl</p><p>Methotrexate sodium</p><p>Metoclopramide HCl</p><p>Mitomycin</p><p>Paclitaxel</p><p>Palonosetron HCl</p><p>Pemetrexed disodium</p><p>Piperacillin sodium–tazobactam sodium</p><p>Potassium chloride</p><p>Propofol</p><p>Sargramostim</p><p>Teniposide</p><p>Thiotepa</p><p>Vinblastine sulfate</p><p>Vincristine sulfate</p><p>Incompatible</p><p>Aldesleukin</p><p>Amphotericin B cholesteryl sulfate complex</p><p>Droperidol</p><p>Filgrastim</p><p>Gallium nitrate</p><p>Topotecan HCl</p><p>Vinorelbine tartrate</p><p>Variable</p><p>Ondansetron HCl</p><h2>Actions</h2><ul>
<li>
<p>Precise mechanisms of action of fluorouracil have not been fully elucidated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>May interfere with DNA synthesis, RNA processing, and protein synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;358&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Main mechanism may be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N<sup>5–10</sup>-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex, which inhibits the formation of thymidylate from uracil, interfering with DNA synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;358&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>In addition, FUTP can be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;358&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Precise mechanisms of action of fluorouracil have not been fully elucidated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May interfere with DNA synthesis, RNA processing, and protein synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;358&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Main mechanism may be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N<sup>5–10</sup>-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex, which inhibits the formation of thymidylate from uracil, interfering with DNA synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;358&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In addition, FUTP can be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;358&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Advise patients about expected toxic effects, especially oral manifestations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that alopecia is possible, but usually transient.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Advise patients about expected toxic effects, especially oral manifestations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that alopecia is possible, but usually transient.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;205&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV use</p><p>50 mg/mL*</p><p>Adrucil<sup></sup></p><p>Teva</p><p>Fluorouracil Injection</p><p>50 mg/mL (2.5 or 5 g) pharmacy bulk package*</p><p>Adrucil<sup></sup></p><p>Teva</p><p>Fluorouracil Injection</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions July 9, 2013. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>200. Machover D, Schwarzenberg L, Goldschmidt E et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. <i>Cancer Treat Rep</i>. 1982; 66:1803-7. http://www.ncbi.nlm.nih.gov/pubmed/6982099?dopt=AbstractPlus</p><p>201. Budd GT, Fleming TR, Bukowski RM et al. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group study. <i>J Clin Oncol</i>. 1987; 5:272-7. http://www.ncbi.nlm.nih.gov/pubmed/3543246?dopt=AbstractPlus</p><p>202. Panasci L, Ford J, Margolese R. A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. <i>Cancer Chemother Pharmacol</i>. 1985; 15:164-6. http://www.ncbi.nlm.nih.gov/pubmed/4017165?dopt=AbstractPlus</p><p>203. Glimelius B, Ginman C, Graffman S et al. Sequential methotrexate-5-FU-leucovorin (MFL) in advanced colorectal cancer. <i>Eur J Cancer Clin Oncol</i>. 1986; 22:295-300. http://www.ncbi.nlm.nih.gov/pubmed/3486768?dopt=AbstractPlus</p><p>204. Hansen RM, Ritch PS, Anderson T. Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma. <i>Am J Clin Oncol</i>. 1986; 9:352-4. http://www.ncbi.nlm.nih.gov/pubmed/3489407?dopt=AbstractPlus</p><p>205. Teva Parenteral Medicines Inc. Adrucil<sup></sup> (fluorouracil) injection prescribing information. Irvine, CA; 2007 Jul.</p><p>206. Feldman LD, Ajani JA. Fluorouracil-associated dermatitis of the hands and feet. <i>JAMA</i>. 1985; 254:3479. http://www.ncbi.nlm.nih.gov/pubmed/2933539?dopt=AbstractPlus</p><p>207. Monk MR, Sanchez JD, Phelps CD et al. Myocardial ischemia with fluorouracil and floxuridine therapy. <i>Clin Pharm</i>. 1987; 6:659-61. http://www.ncbi.nlm.nih.gov/pubmed/2961503?dopt=AbstractPlus</p><p>208. Burger AJ, Mannino S. 5-Fluorouracil-induced coronary vasospasm. <i>Am Heart J</i>. 1987; 114:433-6. http://www.ncbi.nlm.nih.gov/pubmed/3604903?dopt=AbstractPlus</p><p>209. Kleiman NS, Lehane DE, Geyer CE Jr et al. Prinzmetal’s angina during 5-fluorouracil chemotherapy. <i>Am J Med</i>. 1987; 82:566-8. http://www.ncbi.nlm.nih.gov/pubmed/3826112?dopt=AbstractPlus</p><p>210. Santos AM, Medina FS. Anaphylactic reaction following IV administration of 5-fluorouracil. <i>Cancer Treat Rep</i>. 1986; 70:1346. http://www.ncbi.nlm.nih.gov/pubmed/3768880?dopt=AbstractPlus</p><p>211. Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. <i>J Clin Oncol</i>. 1986; 4:685-96. http://www.ncbi.nlm.nih.gov/pubmed/3517242?dopt=AbstractPlus</p><p>212. Leone BA, Romero A, Rabinovich MG et al. Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma. <i>J Clin Oncol</i>. 1986; 4:23-7. http://www.ncbi.nlm.nih.gov/pubmed/3941331?dopt=AbstractPlus</p><p>213. Burroughs Wellcome. Wellcovorin<sup></sup> (leucovorin calcium) prescribing information. In: Barnhart ER, publisher. Physicians’ desk reference. 43rd ed. Oradell, NJ: Medical Economics Company Inc; 1989(Suppl B):B8.</p><p>214. Grem JL, Shoemaker DD, Petrelli NJ et al. Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma. <i>Cancer Treat Rep</i>. 1987; 71:1122. http://www.ncbi.nlm.nih.gov/pubmed/3499982?dopt=AbstractPlus</p><p>215. Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. <i>J Clin Oncol</i>. 1989; 7:1419-26. http://www.ncbi.nlm.nih.gov/pubmed/2674331?dopt=AbstractPlus</p><p>216. Petrelli NJ, Madajewicz S, Herrera L et al. Biologic modulation of 5-fluorouracil with high-dose leucovorin and combination chemotherapy of 5-fluorouracil and cisplatin in metastatic colorectal adenocarcinoma. In: Development of folates and folic acid antagonists in cancer chemotherapy. NCI monographs 1987 No. 5. NIH Publication No. 87-2901 Number 5 1987. Bethesda, MD: National Cancer Institute; 1987:189-92.</p><p>217. Bruckner HW, Petrelli NJ, Stablein D et al. Comparison of unique leucovorin and 5-fluorouracil “escalating” and “maximum” dosage strategies. In: Development of folates and folic acid antagonists in cancer chemotherapy. NCI monographs 1987 No. 5. NIH Publication No. 87-2901 Number 5 1987. Bethesda, MD; National Cancer Institute; 1987:179-84.</p><p>218. Erlichman C, Fine S, Wong A et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. <i>J Clin Oncol</i>. 1988; 6:469-75. http://www.ncbi.nlm.nih.gov/pubmed/3280741?dopt=AbstractPlus</p><p>219. Doroshow JH, Bertrand M, Newman E et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. In: Development of folates and folic acid antagonists in cancer chemotherapy. NCI Monograph 1987 No. 5. NIH Publication No. 87-2901, Number 5, 1987. Bethesda, MD; National Cancer Institute; 1987: 171-4.</p><p>220. Petrelli N, Herrera L, Rustum Y et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. <i>J Clin Oncol</i>. 1987; 5:1559-65. http://www.ncbi.nlm.nih.gov/pubmed/2443619?dopt=AbstractPlus</p><p>221. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. <i>Cancer Res</i>. 1981; 41:3288-95. http://www.ncbi.nlm.nih.gov/pubmed/6973389?dopt=AbstractPlus</p><p>222. Lockshin A, Danenberg PV. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. <i>Biochem Pharmacol</i>. 1981; 30:247-57. http://www.ncbi.nlm.nih.gov/pubmed/6939434?dopt=AbstractPlus</p><p>223. Ullman B, Lee M, Martin DW Jr et al. Cytotoxicity of 5-fluoro-2-rdeoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. <i>Proc Natl Acad Sci USA</i>. 1978; 75:980-3. http://www.ncbi.nlm.nih.gov/pubmed/147465?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=411383&amp;blobtype=pdf</p><p>224. Waxman S, Bruckner H, Wagle A et al. Potentiation of 5-fluorouracil (5-FU) antimetabolic effect by leucovorin (LV). <i>Proc Annu Meet Am Assoc Cancer Res Proc Annu Meet Am Soc Clin Oncol</i>. 1978; 19:149.</p><p>225. Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. <i>Mol Pharmacol</i>. 1984; 25:303-9. http://www.ncbi.nlm.nih.gov/pubmed/6608049?dopt=AbstractPlus</p><p>226. Janssen Pharmaceutica. Ergamisol<sup></sup> (levamisole hydrochloride) tablets prescribing information. Piscataway, NJ; 1990 Jun.</p><p>227. Moertel CG, Fleming TR, MacDonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. <i>New Engl J Med</i>. 1990; 322:352-8. http://www.ncbi.nlm.nih.gov/pubmed/2300087?dopt=AbstractPlus</p><p>228. Mayer RJ. Does adjuvant therapy work in colon cancer? <i>New Engl J Med</i>. 1990; 322:399-401. Editorial.</p><p>229. Windle R, Bell PRF, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. <i>Br J Surg</i>. 1987; 74:569-72. http://www.ncbi.nlm.nih.gov/pubmed/3304518?dopt=AbstractPlus</p><p>230. National Institutes of Health Office of Medical Applications of Research. Consensus conference: adjuvant therapy for patients with colon and rectal cancer. <i>JAMA</i>. 1990; 264:1444-50. http://www.ncbi.nlm.nih.gov/pubmed/2202842?dopt=AbstractPlus</p><p>231. Anon. Consensus panel considers adjuvant therapy for colon and rectal cancer, identifies levamisole-fluorouracil as standard in colon cancer. <i>Clin Pharm</i>. 1990; 9:493, 501-2.</p><p>232. Anon. Levamisole with fluorouracil for colon cancer. <i>Med Lett Drugs Ther</i>. 1989; 31:29-30.</p><p>233. Brandman JF. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. <i>New Engl J Med</i>. 1990; 323:197-8. http://www.ncbi.nlm.nih.gov/pubmed/2362611?dopt=AbstractPlus</p><p>234. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. <i>N Engl J Med</i>. 1991; 324:709-15. http://www.ncbi.nlm.nih.gov/pubmed/1997835?dopt=AbstractPlus</p><p>235. Clinical Announcement: Adjuvant Therapy of Rectal Cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 1991 Oct 8.</p><p>236. Moertel CG, Krook JE, Wieand HS. Effective surgical adjuvant therapy for high-risk rectal carcinoma. <i>N Engl J Med</i>. 1991; 325:519-20. http://www.ncbi.nlm.nih.gov/pubmed/1852188?dopt=AbstractPlus</p><p>237. Rectal cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 1991 Oct 8.</p><p>238. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. <i>N Engl J Med</i>. 1991; 324:709-15. http://www.ncbi.nlm.nih.gov/pubmed/1997835?dopt=AbstractPlus</p><p>239. O’Connell M, Wieand H et al. Lack of value for methyl-CCNU (MeCCNU) as a component of effective rectal cancer surgical adjuvant therapy: interim analysis of intergroup protocol 86-47-51. Paper presented at the Proceedings of the American Society for Clinical Oncology, 1991 May.</p><p>240. Reynolds T. Combined treatment substantially improves outlook for rectal cancer. <i>J Natl Cancer Inst</i>. 1991; 83:386-7. http://www.ncbi.nlm.nih.gov/pubmed/1999843?dopt=AbstractPlus</p><p>241. Ovarian epithelial cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jul.</p><p>242. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. <i>N Engl J Med</i>. 1985; 312:1465-72. http://www.ncbi.nlm.nih.gov/pubmed/2859523?dopt=AbstractPlus</p><p>243. Gastrointestinal Tumor Study Group. Survival after postoperative combination treatment of rectal cancer. <i>N Engl J Med</i>. 1986; 315:1294-5. http://www.ncbi.nlm.nih.gov/pubmed/3773947?dopt=AbstractPlus</p><p>244. Breast cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 1995 Dec 12.</p><p>245. Fisher B, Redmond C, Dimitrov NV et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. <i>N Engl J Med</i>. 1989; 320:473-8. http://www.ncbi.nlm.nih.gov/pubmed/2644531?dopt=AbstractPlus</p><p>246. McGuire WL. Adjuvant therapy of node-positive breast cancer. <i>N Engl J Med</i>. 1989; 320:525-7. http://www.ncbi.nlm.nih.gov/pubmed/2915655?dopt=AbstractPlus</p><p>247. De Vita VT Jr. Breast cancer therapy: exercising all our options. <i>N Engl J Med</i>. 1989; 320:527-9. http://www.ncbi.nlm.nih.gov/pubmed/2915656?dopt=AbstractPlus</p><p>248. Fisher B, Redmond C, Wickerham LD et al. Systemic therapy in patients with node-negative breast cancer: a commentary based on two National Surgical Adjuvant Breast and Bowel project (NSABP) clinical trials. <i>Ann Intern Med</i>. 1989; 111:703-12. http://www.ncbi.nlm.nih.gov/pubmed/2679288?dopt=AbstractPlus</p><p>249. Anon. Drugs of choice for cancer chemotherapy. <i>Med Lett Drugs Ther</i>. 2000; 42:83-92. http://www.ncbi.nlm.nih.gov/pubmed/10994034?dopt=AbstractPlus</p><p>250. Anon. Adjuvant chemotherapy of early breast cancer. <i>Med Lett Drugs Ther</i>. 1990; 32:49-50. http://www.ncbi.nlm.nih.gov/pubmed/2333039?dopt=AbstractPlus</p><p>251. National Institutes of Health Office of Medical Applications of Research. Consensus conference: treatment of early-stage breast cancer. <i>JAMA</i>. 1991; 265:391-5. http://www.ncbi.nlm.nih.gov/pubmed/1984541?dopt=AbstractPlus</p><p>252. Laurie JA, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. <i>J Clin Oncol</i>. 1989; 7:1447-56. http://www.ncbi.nlm.nih.gov/pubmed/2778478?dopt=AbstractPlus</p><p>253. Colon cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 1991 Oct 8.</p><p>254. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. <i>Ann Intern Med</i>. 1991; 114:621-8. http://www.ncbi.nlm.nih.gov/pubmed/2003707?dopt=AbstractPlus</p><p>255. Chrisp P, McTavish D. Levamisole/fluorouracil: a review of their pharmacology and adjuvant therapeutic use in colorectal cancer. <i>Drugs &amp; Aging</i>. 1991; 1:317-37.</p><p>256. Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. <i>J Natl Cancer Inst</i>. 1988; 80:30-6. http://www.ncbi.nlm.nih.gov/pubmed/3276901?dopt=AbstractPlus</p><p>257. Taylor I, Machin D, Mullee M et al. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. <i>Br J Surg</i>. 1985; 72:359-63. http://www.ncbi.nlm.nih.gov/pubmed/3888335?dopt=AbstractPlus</p><p>258. Wolmark N, Rockette H, Wickerham DL et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of the National Surgical Adjuvant Breast and Bowel Project Protocol C-02. <i>J Clin Oncol</i>. 1990; 8:1466-75. http://www.ncbi.nlm.nih.gov/pubmed/2202789?dopt=AbstractPlus</p><p>259. Beart RW Jr, Moertel CG, Wieand HS et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion: a study of the Mayo Clinic and the North Central Cancer Treatment Group. <i>Arch Surg</i>. 1990; 125:897-901. http://www.ncbi.nlm.nih.gov/pubmed/2369315?dopt=AbstractPlus</p><p>260. Stagg RJ, Venook AP, Chase JL et al. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. <i>J Natl Cancer Inst</i>. 1991; 83:423-8. http://www.ncbi.nlm.nih.gov/pubmed/1825674?dopt=AbstractPlus</p><p>261. Mayer RJ, O’Connell MJ, Tepper JE et al. Status of adjuvant therapy for colorectal cancer. <i>J Natl Cancer Inst</i>. 1989; 81:1359-64. http://www.ncbi.nlm.nih.gov/pubmed/2674456?dopt=AbstractPlus</p><p>262. Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. <i>J Clin Oncol</i>. 1989; 7:1419-26. http://www.ncbi.nlm.nih.gov/pubmed/2674331?dopt=AbstractPlus</p><p>263. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. <i>J Natl Cancer Inst</i>. 1988; 80:21-9. http://www.ncbi.nlm.nih.gov/pubmed/3276900?dopt=AbstractPlus</p><p>264. Gerard A, Buyse M, Pector JC et al. Hepatic artery ligation with and without portal infusion of 5-FU: a randomized study in patients with unresectable liver metastases from colorectal carcinoma. <i>Eur J Surg Oncol</i>. 1991; 17:289-94. http://www.ncbi.nlm.nih.gov/pubmed/2044783?dopt=AbstractPlus</p><p>265. Machiavelli M, Leone BA, Romero A et al. Advanced colorectal carcinoma: a prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. <i>Am J Clin Oncol</i>. 1991; 14:211-7. http://www.ncbi.nlm.nih.gov/pubmed/2031508?dopt=AbstractPlus</p><p>266. Doroshow JH, Multhauf P, Leong L et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. <i>J Clin Oncol</i>. 1990; 8:491-501. http://www.ncbi.nlm.nih.gov/pubmed/2407810?dopt=AbstractPlus</p><p>267. Scheithauer W, Rosen H, Scheissel R et al. Treatment of patients with colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin. <i>Cancer</i>. 1991; 67:1294-8. http://www.ncbi.nlm.nih.gov/pubmed/1991292?dopt=AbstractPlus</p><p>268. Rosen PP, Groshen S, Kinne DW. Prognosis in T2NOMO stage I breast carcinoma: a 20-year follow-up study. <i>J Clin Oncol</i>. 1991; 9:1650-61. http://www.ncbi.nlm.nih.gov/pubmed/1875222?dopt=AbstractPlus</p><p>269. Rosen PP, Groshen S, Saigo PE et al. Pathological prognostic factors in stage I (T1NOMO) and stage II (T1N1MO) breast carcinoma: a study of 644 patients with median follow-up of 18 years. <i>J Clin Oncol</i>. 1989; 7:1239-51. http://www.ncbi.nlm.nih.gov/pubmed/2549203?dopt=AbstractPlus</p><p>270. Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. <i>N Engl J Med</i>. 1988; 319:1681-92. http://www.ncbi.nlm.nih.gov/pubmed/3205265?dopt=AbstractPlus</p><p>271. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. <i>N Engl J Med</i>. 1989; 320:491-6. http://www.ncbi.nlm.nih.gov/pubmed/2644533?dopt=AbstractPlus</p><p>272. Mansour EG, Gray R, Shatila AH et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup study. <i>N Engl J Med</i>. 1989; 320:485-90. http://www.ncbi.nlm.nih.gov/pubmed/2915651?dopt=AbstractPlus</p><p>273. Rubens RD. Breast cancer. In: Pinedo HM, ed. Cancer chemotherapy. Annual 1. New York: Elsevier North Holland, Inc; 1979:376-411.</p><p>274. Agitated by fluorouracil. USP Drug Product Quality Review. 1991; (Apr)17.</p><p>275. Reviewers’ comments (personal observations).</p><p>276. Muss HB, Case LD, Richards F II et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. <i>N Engl J Med</i>. 1991; 325:1342-8. http://www.ncbi.nlm.nih.gov/pubmed/1922236?dopt=AbstractPlus</p><p>277. Norton L. Metastatic breast cancer: length and quality of life. <i>N Engl J Med</i>. 1991; 325:1370-1. http://www.ncbi.nlm.nih.gov/pubmed/1922240?dopt=AbstractPlus</p><p>278. Coates A, Gebski V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. <i>N Engl J Med</i>. 1987; 317:1490-5. http://www.ncbi.nlm.nih.gov/pubmed/3683485?dopt=AbstractPlus</p><p>279. Tannock IF. Treating the patient, not just the cancer. <i>N Engl J Med</i>. 1987; 1534-5. Editorial.</p><p>280. Slevin ML, Gray R. Adjuvant therapy for cancer of the colon: an important step forward. <i>BMJ</i>. 1991; 302:1100-1. http://www.ncbi.nlm.nih.gov/pubmed/2043778?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1669785&amp;blobtype=pdf</p><p>281. O’Connell M, Poon M, Wieand C et al. Biochemical modulation of 5-fluorouracil (5FU) with leucovorin (LV): confirmatory evidence of improved therapeutic efficacy in the treatment of advanced colorectal cancer. <i>Proc ASCO</i>. 1990; 9:106.</p><p>282. Jones SE, Moon TE, Bonadonna G et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. <i>Am J Clin Oncol</i>. 1987; 10:387-95. http://www.ncbi.nlm.nih.gov/pubmed/3310603?dopt=AbstractPlus</p><p>283. Buzdar AU, Kau SW, Smith TL et al. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. <i>Am J Clin Oncol</i>. 1989; 12:123-8. http://www.ncbi.nlm.nih.gov/pubmed/2705401?dopt=AbstractPlus</p><p>284. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. <i>N Engl J Med</i>. 1976; 294:405-10. http://www.ncbi.nlm.nih.gov/pubmed/1246307?dopt=AbstractPlus</p><p>285. Smith DC, Ross DJ, Russell AR et al. Adjuvant chemotherapy in early breast cancer. <i>Br J Cancer</i>. 1979; 40:310.</p><p>286. Bedford Laboratories. Leucovorin calcium powder for injection and solution for injection prescribing information. Bedford, OH; 2008 Sep.</p><p>287. Rectal cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Library of Medicine; 1992 June 8.</p><p>288. Colon cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Library of Medicine; 1992 June 8.</p><p>289. Lederle. Combination chemotherapy with leucovorin calcium and 5-fluorouracil. Pearl River, NY; 1992 Mar.</p><p>290. DeLap RJ. The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients. <i>Yale J Biol Med</i>. 1988; 61:23-34. http://www.ncbi.nlm.nih.gov/pubmed/3284210?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2590394&amp;blobtype=pdf</p><p>291. Saltz L. Drug treatment of colorectal cancer: current status. <i>Drugs</i>. 1991; 42:616-27. http://www.ncbi.nlm.nih.gov/pubmed/1723364?dopt=AbstractPlus</p><p>292. Erlichman C. Fluorouracil and leucovorin for metastatic colorectal cancer. <i>J Chemother</i>. 1990; 2(Suppl 1):38-40. http://www.ncbi.nlm.nih.gov/pubmed/2195136?dopt=AbstractPlus</p><p>293. O’Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer: a Mayo Clinic/North Central Cancer Treatment Group study. <i>Cancer</i>. 1989; 63:1026-30. http://www.ncbi.nlm.nih.gov/pubmed/2465076?dopt=AbstractPlus</p><p>294. Poon MA, O’Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. <i>J Clin Oncol</i>. 1989; 7:1407-18. http://www.ncbi.nlm.nih.gov/pubmed/2476530?dopt=AbstractPlus</p><p>295. Poon MA, O’Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal carcinoma. <i>J Clin Oncol</i>. 1991; 9:1967-72. http://www.ncbi.nlm.nih.gov/pubmed/1941055?dopt=AbstractPlus</p><p>296. Valone FH, Friedman MA, Wittinger PS et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. <i>J Clin Oncol</i>. 1989; 7:1427-36. http://www.ncbi.nlm.nih.gov/pubmed/2789272?dopt=AbstractPlus</p><p>297. Erlichman C. Fluorouracil/leucovorin study update. <i>J Clin Oncol</i>. 1991; 9:2076. http://www.ncbi.nlm.nih.gov/pubmed/1941066?dopt=AbstractPlus</p><p>298. Nobile MT, Canobbio L, Sobrero A et al. A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high-dose leucovorin in untreated advanced colorectal cancer patients. <i>Adv Exp Med Biol</i>. 1988; 244:213-8. http://www.ncbi.nlm.nih.gov/pubmed/3073656?dopt=AbstractPlus</p><p>299. Loffler TM, Weber FW, Hausamen TU. Protracted continuous-infusion 5-fluorouracil with intermittent high-dose leucovorin in advanced and metastatic colorectal cancer: a pilot study. In: Pinedo HM, Rustum YM, eds. Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. New York: Royal Society of Medicine Services; 1989:65-8.</p><p>300. Labianca R, Pancera G, Aitini E et al. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of “GISCAD” (Italian Group for the Study of Digestive Tract Cancer). <i>Ann Oncol</i>. 1991; 2:673-9. http://www.ncbi.nlm.nih.gov/pubmed/1742223?dopt=AbstractPlus</p><p>301. Hines JD, Adelstein DJ, Speiss JL et al. Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. <i>Cancer</i>. 1989; 63(Suppl):1022-5. http://www.ncbi.nlm.nih.gov/pubmed/2783879?dopt=AbstractPlus</p><p>302. Laufman LR, Brenckman WD Jr, Stydnicki KA et al. Clinical experience with leucovorin and 5-fluorouracil. <i>Cancer</i>. 1989; 63(Suppl):1031-5. http://www.ncbi.nlm.nih.gov/pubmed/2783880?dopt=AbstractPlus</p><p>303. Rustum YM. Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience. <i>J Chemother</i>. 1990; 2(Suppl 1):5-11. http://www.ncbi.nlm.nih.gov/pubmed/2195138?dopt=AbstractPlus</p><p>304. Gerstner J, O’Connell MJ, Wieand HS et al. A prospectively randomized clinical trial comparing 5-FU combined with either high- or low-dose leucovorin for the treatment of advanced colorectal cancer. <i>Proc Annu Meet Am Soc Clin Oncol</i>. 1991; 10:A404.</p><p>305. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. <i>J Clin Oncol</i>. 1992; 10:896-903. http://www.ncbi.nlm.nih.gov/pubmed/1534121?dopt=AbstractPlus</p><p>306. Mini E, Trave F, Rustum YM et al. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. <i>Pharmacol Ther</i>. 1990; 47:1-19. http://www.ncbi.nlm.nih.gov/pubmed/2195551?dopt=AbstractPlus</p><p>307. Romanini A, Lin JT, Niedzwiecki D et al. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. <i>Cancer Res</i>. 1991; 51:789-93. http://www.ncbi.nlm.nih.gov/pubmed/1988119?dopt=AbstractPlus</p><p>308. Machover D. Potentiation of the antitumour activity of the fluoropyrimidines by leucovorin: rationale and clinical data. In: Pinedo HM, Rustum YM, eds. Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. New York: Royal Society of Medicine Services; 1989:1-9.</p><p>309. Rustum YM. Rationale for the combination of 5-fluorouracil/leucovorin: role of dose, schedule and route of administration. In: Pinedo HM, Rustum YM, eds. Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. New York: Royal Society of Medicine Services; 1989:11-19.</p><p>310. Peters GJ, van der Wilt CL, van Groeningen CJ et al. Development of leucovorin/5-fluorouracil combinations. In: Pinedo HM, Rustum YM, eds. Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. New York: Royal Society of Medicine Services; 1989:21-35.</p><p>311. Creaven PJ, Petrelli NJ, Rustum YM. Leucovorin/5-fluorouracil: response and toxicity in relation to quality of life. In: Pinedo HM, Rustum YM, eds. Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. New York: Royal Society of Medicine Services; 1989:57-64.</p><p>312. Wilke H, Preusser P, Stahl M et al. Leucovorin/5-fluorouracil alone or in combination with other cytostatic drugs in the treatment of advanced gastric carcinoma. In: Pinedo HM, Rustum YM, eds. Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. New York: Royal Society of Medicine Services; 1989:87-95.</p><p>313. Schöber CH, Köhne-Wömpner CH, Schmoll HJ et al. A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. <i>Semin Oncol</i>. 1992; 19(Suppl 3):136-40. http://www.ncbi.nlm.nih.gov/pubmed/1557639?dopt=AbstractPlus</p><p>314. Schöber CH, Bokemeyer C, Stahl M et al. The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. <i>Semin Oncol</i>. 1992; 19(Suppl 3):131-5. http://www.ncbi.nlm.nih.gov/pubmed/1557638?dopt=AbstractPlus</p><p>315. Steinke B, Günther E, Hirschmann WD et al. Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer—preliminary results of a randomized trial. <i>Semin Oncol</i>. 1992; 19(Suppl 3):141-7. http://www.ncbi.nlm.nih.gov/pubmed/1557640?dopt=AbstractPlus</p><p>316. Lederle, Pearl River, NY: personal communication.</p><p>317. Nobile MT, Vidili MG, Sobrero A et al. 5-Fluorouracil (FU) alone or combined with high dose folinic acid (FA) in advanced colorectal cancer patients: a randomized trial. <i>Proc Annu Meet Am Soc Clin Oncol</i>. 1988; 7:A371.</p><p>318. O’Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. <i>N Engl J Med</i>. 1994; 331:502-7. http://www.ncbi.nlm.nih.gov/pubmed/8041415?dopt=AbstractPlus</p><p>319. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. <i>Lancet</i>. 1992; 339:1-15,71-85. http://www.ncbi.nlm.nih.gov/pubmed/1345950?dopt=AbstractPlus</p><p>320. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. <i>N Engl J Med</i>. 1976; 294:405-10. http://www.ncbi.nlm.nih.gov/pubmed/1246307?dopt=AbstractPlus</p><p>321. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. <i>N Engl J Med</i>. 1995; 332:901-6. http://www.ncbi.nlm.nih.gov/pubmed/7877646?dopt=AbstractPlus</p><p>322. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. <i>N Engl J Med</i>. 1994; 330:1253-9. http://www.ncbi.nlm.nih.gov/pubmed/8080512?dopt=AbstractPlus</p><p>323. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. <i>JAMA</i>. 1995; 273:542-7. http://www.ncbi.nlm.nih.gov/pubmed/7837388?dopt=AbstractPlus</p><p>324. Fisher B, Constantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. <i>N Engl J Med</i>. 1989; 320:479-84. http://www.ncbi.nlm.nih.gov/pubmed/2644532?dopt=AbstractPlus</p><p>325. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from National Surgical Adjuvant Breast and Bowel Project B-15. <i>J Clin Oncol</i>. 1990; 8:1483-96. http://www.ncbi.nlm.nih.gov/pubmed/2202791?dopt=AbstractPlus</p><p>326. Moliterni A, Bonadonna G, Valagussa P et al. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive nodes. <i>J Clin Oncol</i>. 1991; 9:1124-30. http://www.ncbi.nlm.nih.gov/pubmed/2045854?dopt=AbstractPlus</p><p>327. Fisher B, Redmond C, Wickerman DL et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. <i>J Clin Oncol</i>. 1989; 7:572-82. http://www.ncbi.nlm.nih.gov/pubmed/2651576?dopt=AbstractPlus</p><p>328. Buzzoni R, Bonadonna G, Valagussa P et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. <i>J Clin Oncol</i>. 1991; 9:2134-40. http://www.ncbi.nlm.nih.gov/pubmed/1960555?dopt=AbstractPlus</p><p>329. Esophageal cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jul.</p><p>330. Kelsen DP, Ilson DH. Chemotherapy and combined-modality therapy for esophageal cancer. <i>Chest</i>. 1995; 107:S224-32. http://www.ncbi.nlm.nih.gov/pubmed/7781398?dopt=AbstractPlus</p><p>331. Herskovic A, Martz K, Al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. <i>N Engl J Med</i>. 1992; 326:1593-8. http://www.ncbi.nlm.nih.gov/pubmed/1584260?dopt=AbstractPlus</p><p>332. Haller DG. Treatments for esophageal cancer. <i>N Engl J Med</i>. 1992; 326:1629-31. http://www.ncbi.nlm.nih.gov/pubmed/1584267?dopt=AbstractPlus</p><p>333. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. <i>JAMA</i>. 1999; 281:1623-7. http://www.ncbi.nlm.nih.gov/pubmed/10235156?dopt=AbstractPlus</p><p>334. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia, PA: Lippincott-Raven Publishers; 1997.</p><p>335. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). 1998 Aug 13. From FDA web site (http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm).</p><p>336. Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. <i>Semin Oncol</i>. 1994; 21:474-82. http://www.ncbi.nlm.nih.gov/pubmed/8042045?dopt=AbstractPlus</p><p>337. Oropharyngeal cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jun.</p><p>338. Reviewers’ comments (personal observations) on cisplatin 10:00.</p><p>339. Clark PI, Slevin ML, Reznek RH et al. Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. <i>Int J Color Dis</i>. 1987; 2:26-9.</p><p>340. Wadler S, Schwartz EL, Goldman M et al. Fluorouracil and recombinant alfa-2A-interferon: an active regimen against advanced colorectal carcinoma. <i>J Clin Oncol</i>. 1989; 7:1769-75. http://www.ncbi.nlm.nih.gov/pubmed/2585018?dopt=AbstractPlus</p><p>341. Kemeny N, Younes A, Seiter K et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. <i>Cancer</i>. 1990; 66:2470-5. http://www.ncbi.nlm.nih.gov/pubmed/2249187?dopt=AbstractPlus</p><p>342. Huberman M, Bering H, Tessitore J et al. 5-fluorouracil (5FU) plus recombinant alpha interferon (Roferon A(R)) in advanced colorectal cancer. <i>Proc Am Soc Clin Oncol</i>. 1990; 9:116.</p><p>343. Pazdur R, Abbruzzese J, Faintuch J et al. Phase II study of recombinant interferon alpha (rIFN) and 5-fluorouracil (5-FU) in patients (PTS) with advanced colorectal cancer. <i>Proc Am Soc Clin Oncol</i>. 1990; 9:117.</p><p>344. Yalavarthi P, Murthy S, Budd GT et al. Phase I/II trial of FU, leucovorin (LV) and rHuIFNalpha2a in metastatic colorectal cancer: possible decrease in myelosuppression. <i>Proc Am Soc Clin Oncol</i>. 1990; 9:125.</p><p>345. Wadler S, Lyver A, Goldman M et al. Therapy with 5-fluorouracil (5FU) and recombinant alpha-2A-interferon (IFN) in refractory GI malignancies. <i>Proc Am Soc Clin Oncol</i>. 1989; 8:A384.</p><p>346. Wadler S, Goldman M, Lyver A et al. Phase I trial of 5-fluorouracil and recombinant alpha2a-interferon in patients with advanced colorectal carcinoma. <i>Cancer Res</i>. 1990; 50:2056-9. http://www.ncbi.nlm.nih.gov/pubmed/2317795?dopt=AbstractPlus</p><p>347. Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2A in the treatment of colorectal carcinoma. <i>Semin Oncol</i>. 1990; 17(1 Suppl 1):16-21. http://www.ncbi.nlm.nih.gov/pubmed/2405491?dopt=AbstractPlus</p><p>349. Catimel G. Head and neck cancer: guidelines for chemotherapy. <i>Drugs</i>. 1996; 51:73-88. http://www.ncbi.nlm.nih.gov/pubmed/8741233?dopt=AbstractPlus</p><p>350. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. <i>J Clin Oncol</i>. 1992; 10:257-63. http://www.ncbi.nlm.nih.gov/pubmed/1732427?dopt=AbstractPlus</p><p>351. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. <i>J Clin Oncol</i>. 1992; 10:1245-51. http://www.ncbi.nlm.nih.gov/pubmed/1634913?dopt=AbstractPlus</p><p>352. Merlano M, Vitale V, Rosso R et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. <i>N Engl J Med</i>. 1992; 327:1115-21. http://www.ncbi.nlm.nih.gov/pubmed/1302472?dopt=AbstractPlus</p><p>353. Merlano M, Benasso M, Corvo R et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. <i>J Natl Cancer Inst</i>. 1996; 88:583-9. http://www.ncbi.nlm.nih.gov/pubmed/8609658?dopt=AbstractPlus</p><p>354. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. <i>N Engl J Med</i>. 1993; 328:184-94. http://www.ncbi.nlm.nih.gov/pubmed/8417385?dopt=AbstractPlus</p><p>355. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. <i>N Engl J Med</i>. 1991; 324:1685-90. http://www.ncbi.nlm.nih.gov/pubmed/2034244?dopt=AbstractPlus</p><p>356. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. <i>J Clin Oncol</i>. 1994; 12:1592-9. http://www.ncbi.nlm.nih.gov/pubmed/8040671?dopt=AbstractPlus</p><p>357. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. <i>J Natl Cancer Inst</i>. 1996; 88:890-9. http://www.ncbi.nlm.nih.gov/pubmed/8656441?dopt=AbstractPlus</p><p>358. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. <i>J Clin Oncol</i>. 1988; 6:1653-64. http://www.ncbi.nlm.nih.gov/pubmed/3049954?dopt=AbstractPlus</p><p>359. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. <i>N Engl J Med</i>. 1999; 340:1137-43. http://www.ncbi.nlm.nih.gov/pubmed/10202164?dopt=AbstractPlus</p><p>360. Peters WA III, Liu PY, Barrett R et al. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III Inter-Group Study. In: Abstracts of the 30th Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 1999 Mar 20–24. Abstract.</p><p>361. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. <i>N Engl J Med</i>. 1999; 340:1144-53. http://www.ncbi.nlm.nih.gov/pubmed/10202165?dopt=AbstractPlus</p><p>362. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. <i>J Clin Oncol</i>. 1999; 17:1339-48. http://www.ncbi.nlm.nih.gov/pubmed/10334517?dopt=AbstractPlus</p><p>363. Thomas GM. Improved treatment for cervical cancer—concurrent chemotherapy and radiotherapy. <i>N Engl J Med</i>. 1999; 340:1198-1200. http://www.ncbi.nlm.nih.gov/pubmed/10202172?dopt=AbstractPlus</p><p>364. Cervical cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jun.</p><p>365. Omura GA. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. <i>J Natl Cancer Inst Monogr</i>. 1996; (21):123-6. http://www.ncbi.nlm.nih.gov/pubmed/9023841?dopt=AbstractPlus</p><p>366. Fanning J, Ladd C, Hilgers RD. Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. <i>Gynecol Oncol</i>. 1995; 56:235-8. http://www.ncbi.nlm.nih.gov/pubmed/7896191?dopt=AbstractPlus</p><p>367. Look KY, Blessing JA, Valea FA et al. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. <i>Gynecol Oncol</i>. 1997; 67:255-8. http://www.ncbi.nlm.nih.gov/pubmed/9441772?dopt=AbstractPlus</p><p>368. Reviewers’ comments (personal observations) on cervical cancer.</p><p>369. Look KY, Blessing JA, Gallup DG et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. <i>Am J Clin Oncol</i>. 1996; 19:439-41. http://www.ncbi.nlm.nih.gov/pubmed/8823469?dopt=AbstractPlus</p><p>370. Bonomi P, Blessing J, Ball H et al. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. <i>Gynecol Oncol</i>. 1989; 34:357-9. http://www.ncbi.nlm.nih.gov/pubmed/2767528?dopt=AbstractPlus</p><p>371. Kaern J, Trope C, Sundfoer K et al. Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. <i>Gynecol Oncol</i>. 1996; 60:387-92. http://www.ncbi.nlm.nih.gov/pubmed/8774643?dopt=AbstractPlus</p><p>372. Thomas GM, Dembo AJ, Black B et al. Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery. <i>Gynecol Oncol</i>. 1987; 27:254-63. http://www.ncbi.nlm.nih.gov/pubmed/3114057?dopt=AbstractPlus</p><p>373. Eifel PJ. Concurrent chemotherapy and radiation: a major advance for women with cervical cancer. <i>J Clin Oncol</i>. 1999; 17:1334-5. http://www.ncbi.nlm.nih.gov/pubmed/10334515?dopt=AbstractPlus</p><p>374. Kish JA, Wolf M, Crawford ED et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. <i>Cancer</i>. 1994; 74:916-9. http://www.ncbi.nlm.nih.gov/pubmed/8039119?dopt=AbstractPlus</p><p>375. Atzpodien J, Kirchner H, Lopez Hanninen E et al. Alpha-interferon, interleukin-2 and 5-fluorouracil as a promising biochemotherapy regimen for the management of advanced renal cell carcinoma. <i>Proc Annu Meet Am Soc Clin Oncol</i>. 1993; 12:A708.</p><p>376. Sella A, Zukiwski A, Robinson E et al. Interleukin-2 (IL-2) with interferon-alfa (IFN-alpha) and 5-fluorouracil (5-FU) in patients (pts) with metastatic renal cell cancer (RCC). <i>Proc Annu Meet Am Soc Clin Oncol</i>. 1994; 13:A733.</p><p>377. Lopez Hanninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. <i>J Urol</i>. 1996; 155:19-25. http://www.ncbi.nlm.nih.gov/pubmed/7490829?dopt=AbstractPlus</p><p>378. Ellerhorst JA, Sella A, Amato RJ et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. <i>Cancer</i>. 1997; 80:2128-32. http://www.ncbi.nlm.nih.gov/pubmed/9392335?dopt=AbstractPlus</p><p>379. Ravaud A, Audhuy B, Gomez F et al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d’Immunotherapie. <i>J Clin Oncol</i>. 1998; 16:2728-32. http://www.ncbi.nlm.nih.gov/pubmed/9704724?dopt=AbstractPlus</p><p>380. Tourani JM, Pfister C, Berdah JF et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. <i>J Clin Oncol</i>. 1998; 16:2505-13. http://www.ncbi.nlm.nih.gov/pubmed/9667271?dopt=AbstractPlus</p><p>381. Dutcher JP, Atkins M, Fisher R et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. <i>Cancer J Sci Am</i>. 1997; 3(Suppl 1):S73-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2597550&amp;blobtype=pdf</p><p>382. Igarashi T, Marumo K, Onishi T et al. Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer. <i>Urology</i>. 1999; 53:53-9. http://www.ncbi.nlm.nih.gov/pubmed/9886588?dopt=AbstractPlus</p><p>383. Elias L, Blumenstein BA, Kish J et al. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. <i>Cancer</i>. 1996; 78:1085-8. http://www.ncbi.nlm.nih.gov/pubmed/8780547?dopt=AbstractPlus</p><p>384. Haarstad H, Jacobsen AB, Schjolseth SA et al. Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. <i>Ann Oncol</i>. 1994; 5:245-8. http://www.ncbi.nlm.nih.gov/pubmed/8186172?dopt=AbstractPlus</p><p>385. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. <i>Cancer</i>. 1997; 80:1198-220. http://www.ncbi.nlm.nih.gov/pubmed/9317170?dopt=AbstractPlus</p><p>386. Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. <i>J Clin Oncol</i>. 2005; 23:8671-8. http://www.ncbi.nlm.nih.gov/pubmed/16314627?dopt=AbstractPlus</p><p>387. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. <i>J Clin Oncol</i>. 2004; 22:3766-75. http://www.ncbi.nlm.nih.gov/pubmed/15365073?dopt=AbstractPlus</p><p>388. Stage III colon cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2008 Oct 23.</p><p>389. Stage IV and recurrent colon cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2008 Oct 23.</p><p>390. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. <i>J Clin Oncol</i>. 1997; 15:808-15. http://www.ncbi.nlm.nih.gov/pubmed/9053508?dopt=AbstractPlus</p><p>391. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. <i>J Clin Oncol</i>. 2006; 24:394-400. http://www.ncbi.nlm.nih.gov/pubmed/16421419?dopt=AbstractPlus</p><p>392. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. <i>J Clin Oncol</i>. 1995; 13:1303-11. http://www.ncbi.nlm.nih.gov/pubmed/7751875?dopt=AbstractPlus</p><p>393. Sanofi-Aventis. Taxotere<sup></sup> (docetaxel) injection concentrate prescribing information. Bridgewater, NJ; 2011 Sept.</p><p>394. Accord Healthcare, Inc. Docetaxel injection prescribing information. Durham, NC; 2011 Jun.</p><p>395. Spectrum Pharmaceuticals, Inc. Fusilev<sup></sup> (levoleucovorin calcium) powder for injection and solution for injection prescribing information. Irvine, CA; 2011 Apr.</p><p>397. Goldberg RM, Hatfield AK, Kahn M et al. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. <i>J Clin Oncol</i>. 1997; 15:3320-9. http://www.ncbi.nlm.nih.gov/pubmed/9363861?dopt=AbstractPlus</p><p>a. AHFS drug information 2004. McEvoy GK, ed. Fluorouracil. Bethesda, MD: American Society of Health-System Pharmacists; 2004:1000-5.</p><p>b. Anon. Drugs of choice for cancer. Treat Guidel. <i>Med Lett</i>. 2003; 1:41-52.</p><p>HID. Trissel LA. Handbook on injectable drugs 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:523-30.</p><h2>More about fluorouracil</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antimetabolites</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fluorouracil Intravenous, Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Fluorouracil Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Anal Cancer</li>
<li>Breast Cancer</li>
<li>Breast Cancer, Palliative</li>
<li>Cancer</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>